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Abstract: Introduction: During osseointegration process, the presence of an inflammatory event
could negatively influence the proper osteogenetic ability of the implant surface. In order to reduce
this possibility, an implementation of angiogenetic event through the release of Vascular Endothelial
Growth Factor (VEGF) can be a tool as co-factor for osteoblastic differentiation. In this paper,
novel dental implant surfaces enriched with VEGF have been tested. Material and methods: The
ability of VEGF-enriched titanium implants to improve the osteogenetic properties of Mesenchymal
stem cells (MSC), also in the presence of an inflammatory environment, have been in vitro tested.
Molecular biology, morphological analyses, and biochemical tests have been performed in order to
confirm biological properties of these surfaces. Results: Our results confirm that the presence of VEGF
onto the implant surface is able not only to protect the cells from in vitro aging and from Reactive
Oxygen Species (ROS) damage, but it also improves their osteogenic and endothelial differentiation,
even in the presence of inflammatory cytokines. Conclusion: This study establishes a biologically
powerful novel tool that could enhance bone repair in dental implant integration.
Keywords: biomimetic material; cell adhesion; osteogenesis; osseointegration; vascular endothelial
growth factor
1. Introduction
A prerequisite for clinical success in dental implant surgery is implant osseointegration [1].
Several modifications of the implant surface, such as calcium-phosphate ceramic coatings,
modification on macro/microporosity, or different surface treatments have been developed showing
limited success in promoting integration [2–4]. Recent surface modification strategies directed at
improving bone regeneration and osseointegration have involved the immobilization of Extracellular
Matrix Components (ECM). This would facilitate the interaction with cellular integrin receptors,
thus activating signaling pathways that promote osteoblastic differentiation and subsequent matrix
mineralization [5,6]. The ECM proteins have therefore represented attractive targets for functionalizing
surfaces of biomaterial thanks to their inherent bioactivity. Nevertheless, they have showed
immunogenicity and complexities related to their purification and processing. Other strategies
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have focused their attention on short synthetic peptides that present the bioadhesive motif,
such as peptides containing the arginine-glycine-aspartic acid (RGD) sequence, which mediates
cell attachment to several matrix proteins, including vitronectin, fibronectin, bone sialoprotein,
and osteopontin. However, these bio-inspired strategies have produced only marginal increases in
implant osseointegration and mechanical fixation [7–9]. These disappointing results could find a reply
in the lack of selectivity among integrins and, consequently, in non-discriminatory cell attachment.
In recent years, a novel therapeutic application has been based on the use of growth factors to
improve regeneration of tissue since they are critical elements for new tissue production. In addition,
in case of regenerative surgery they are able to perform feedback controls on inflammatory processes
within the tissue graft [10,11]. Growth factors do not pass through a cell’s membrane, due to their
ability to bind high-affinity cell receptors to take effect. Many growth factors are present in the ECM
where they can be released during matrix degradation, thus acting during tissue remodeling and
regeneration. In this context, several growth factors have been applied to bone regeneration strategies.
One of the first used is Transforming Growth Factor-β (TGFβ) whose effect is highly variable and
dependent on the type of cells and tissues. TGFβ regulates a broad range of cellular activities, such as
cell proliferation, cell migration, cell differentiation, and ECM synthesis [12,13]. TGFβ promotes
odontoblastic differentiation of Dental Pulp Stem Cells (DPSCs) and plays an important role in the
immune response during the dental pulp injury [14]. Another growth factor used in bone regeneration
is Bone Morphogenetic Protein (BMP) that belong to the TGFβ superfamily [15]. BMPs play important
roles in the development and remodeling of the bone, promoting chemotaxis and aggregation of
cells into osteogenic sites facilitating the differentiation of Mesenchymal Stem Cells (MSCs) into
osteoblasts [16,17]. To date, more than 20 different forms of BMPs have been identified, and they
are considered as the most potent growth factors promoting bone regeneration [18]. Other growth
factors are used in regenerative medicine of the bone. These are represented by Fibroblast Growth
Factor (FGF), which dramatically induces the mRNA expression of Dentin Sialophosphoprotein (DSPP)
and Bone Sialoprotein (BSP) in immature adult rat incisor dental pulp cells [19,20], and Insulin-like
Growth Factor (IGF), which contributes to odontogenesis and dental tissue repair by cell proliferation
and differentiation [21,22]. In this context, we have focused our attention on Vascular Endothelial
Growth Factor (VEGF). VEGF is a heparin-binding protein with particular affinity to endothelial cells
and plays a key role in angiogenesis [23,24]. For a long time, VEGF has been mainly considered as
a potent mitogenic factor for vascular endothelial cells, involved in the modulation of physiological
angiogenesis, vascular permeability and also the occurrence/progression of tissue inflammation.
More recently, VEGF has been recognized as a positive regulator of bone development, skeletal growth,
and fracture repair, also stimulating proliferation and differentiation of bone-derived osteoblasts [25,26].
In addition, it has been reported that VEGF is involved in regulation of adipogenesis and osteogenesis
in MSCs. VEGF is highly expressed in osteoblastic precursor cells and now it is known to stimulate
bone formation [27]. Moreover, researchers tested the hypothesis that this growth factor could exert
an important role as regulator of cell fate [28,29]. In particular, the authors suggest that VEGF could
determine the differentiation that gives rise to osteoblasts or adipocytes. These results supported the
model whereby VEGF regulates the commitment through an intracrine mechanism that is distinct
from the role of secreted VEGF and its receptors.
In the present study, we have developed a titanium dental implant loaded with VEGF in order
to improve osteogenesis during implant surgery. We hypothesized that coating titanium implants
with this growth factor could enhance peri-implant bone formation and mechanical osseointegration,
thus providing a simple, clinically relevant strategy for improving implant osseointegration.
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2. Results
2.1. In Vitro Release of VEGF
In order to test the ability of VEGF-enriched dental implants to release VEGF in vitro,
we quantified the growth factor in the cell culture medium up to 7 days by means of an ELISA
test. As reported in Figure 1, VEGF concentration increases in the medium in a time-dependent
manner, starting from a basal concentration of 180 ng/mL after 1 h and reaching the maximum level of
1800 ng/mL after 24 h.
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2.2. Biocompatibility and Cell Proliferation
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay has been
performed in order to test the implants’ biocompatibility. As shown in Figure 2a,b, human DPSCs
were able to proliferate both on the control and VEGF-enriched implant surface with no statistical
difference between the two surfaces. During culturing time, cells increase in number as demonstrated
by the incre sing value recorded. On the con rary, DPSCs treatment with the nflammatory cytokine
Tumor N crosis Fact r alpha (TNFα) induces a significant decrease in cell proliferation both on the
control and the VEGF-enriched surface.
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of b rs and b: in fo m of line). Cells are able to proliferat on both the c trol and VEGF-enriched
surface from 3 to 28 days of culture with no statistical difference between the two surfaces. On the
contrary, when cells are treated with Tumor Necrosis Factor α (TNFα) their proliferation is significantly
reduced on both the control and the VEGF-enriched implant; (c,d) Quantification of intracellular
Lactate Dehydrogenase (LDH) activity (c: in form of bars; d: in form of lines). Intracellular LDH
activity proves that cells are able to produce metabolites if seeded onto both surfaces, with improved
results fter 7 days from seeding; (e,f) Quantification of extracellular LDH activity (e: in form of bars;
f: in for of lines). Extracellular LDH activity confirms that metabol es are secreted by the cells and
are not associated with damage of the membrane. Statistically significant differences are indicated as
* p < 0.05, ** p < 0.01, and compared with the control condition.
2.3. Intracellular and Extracellular Lactate Dehydrogenase (LDH) Activity
Damage on cells surface has been evaluated with LDH activity assay. Figure 2c,d, related to
intracellular LDH activity, shows that DPSCs were able to produce metabolites if seeded onto both
surfaces, with improved results after 7 days from seeding. In Figure 2e,f, extracellular LDH activity
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is reported. Presence of LDH in extracellular compartment is generally correlated to a membrane
damage, and this could be possibly due to the scaffold composition. The LDH activity measured in
the culture medium confirms that there was no damage associated to the membrane. In addition,
no difference between the two surfaces has been detected.
2.4. Reactive Oxygen Species (ROS) Production
Analysis of intracellular redox equilibrium has been performed to test if VEGF released by
the implant surface could induce oxidative stress, able to generate some modifications in signaling
pathways. As reported in Figure 3a,b, a weak time-dependent increase in metabolic activity has been
observed in cells seeded onto both surfaces. During culturing time, when DPSCs were seeded onto the
VEGF-enriched dental implants, lower ROS level was recorded with respect to the value obtained from
cells cultured onto control surfaces. Under inflammatory conditions, ROS production increased but,
also in this case, the presence of VEGF onto the implants induced a small reduction in the measured
ROS value.
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Figure 3. (a,b) (a: in form of bars and b: in form of line). Reactive Oxygen Speci s (ROS) production f
Dental Pulp Stem Cells (DPSCs) seeded onto VEGF-enriched or control dental implants. Histograms show
a slight ti e-dependent increase in metabolic activity in cells seeded onto both surfaces. The presence
of VEGF on the implant surface is able to reduce the intracellular ROS production, especially under
inflammatory conditions. Results are expressed as fluorescent arbitrary units per second (f.a.u./s);
(c,d) (c: in form of bars and d: in form of line). Evaluation of Senescence-associated beta-galactosidase
(SA-b GAL) (SA-b GAL) activity of DPSCs under normal or inflammatory conditions on surfaces
combined or not with VEGF. Results show that cells cultured on implants loaded with VEGF have
a lower SA-b GAL activity value compared to the cells seeded on the control one.
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2.5. Senescence
The presence of an inflammatory environment could affect normal cell growth, inducing the cells
to enter in a state of irreversible arrested growth with altered functions. The senescence activity of
stem cells following their in vitro culture has been evaluated by the β-galactosidase staining at selected
time points of (3, 7, 14, 21 and 28 days), both in normal condition and in presence of inflammatory
cytokines on surfaces enriched with VEGF or without it. As reported in Figure 3c,d, we observed an
in vitro age-dependent increase in the Senescence-associated beta-galactosidase (SA-b GAL) activity.
In particular, our results showed that cells cultured on implants containing VEGF had a lower SA-b
GAL activity value compared to the cells cultured on the control ones. These results suggest that the
aging effect on cells would be decreased by the VEGF treatment of dental implants.
2.6. Cell Morphology
DPSCs were found to adhere to the dental implant surface, as revealed by the staining with the
fluorescent phalloidin (Figure 4). After 7 days of culture, cells had colonized the implant surfaces and
assumed the star-like morphology typically associated to an osteoblastic phenotype. After 14 days,
cells were able to spread on all the implant surface.
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A detailed analysis of cell shape has additionally been performed. In particular, the Circularity,
Roundness, and Solidity parameters have been considered. As shown in Figure 5, when cells were
seeded onto the VEGF-enriched implants and cultured for 14 days, they assumed an elongated
morphology, as suggested by the Circularity and Roundness calculated values. This would confirm
that the cells lost the staminal rounded aspect for acquiring a more elongated morphology.
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the expres ion of several o te genic markers, such as Alkaline phosph tas activity (ALP), Runx,
osteopontin, osteonectin, osteocalcin, collagen type I, and endothelial markers, such as CD31,
von Willebrand and VEGF by means of biochemical (for ALP) and with real-time PCR after 21 days of
cultures. Tests were performed on cells seeded on implants loaded with VEGF or without it, both in
normal condition and in presence of inflammatory cytokines.
To confirm the early differentiation of cell towards osteoblast phenotype, the ALP activity
(expressed as U/mL that is the amount of enzyme causing the hydrolysis of one micromole of pNPP
per units per mL) was quantified into all cells condition. As reported on Figure 7, the extracellular
ALP was higher in the VEGF-impregnated group than the controls (polystyrene and normal implant
group), where it was lower (0.24 U/m ). T note, in all cases the presence of inflammatory condition
induces an inc ase of ALP productio .
As reported in Figur 8a, an increase in the expression of the osteogenic a d endothelial markers
was observed in all the conditions, thus confirming that the presence of VEGF exerts a positive effect
on the differentiation process, even in the presence of an inflammatory environment.
In order to better understand the intracellular signaling pathways involved in the commitment of
stem cells onto the osteogenic phenotype, a real-time PCR for the mTOR pathway markers has been
performed. Results reported in Figure 8b show that, not only did the presence of VEGF improve the
expression of this important factor, but it also induced an increase of its related proteins, such as AKT,
MAPK1 and RRAGA. In addition, an increased expression has been detected for VEGF and Rho family
of GTPases (RHO), which are involved in mechano-transduc ion fu cti . To note, the presence of
VEGF on the implant’s surface improved the commitment of DPSCs onto the osteogenic phenotype
even under inflammatory conditions.
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3. Discussion
One of the principal factors inducing new tissue regeneration, i.e., when a dental implant
is inserted into the bone or promoting tissue regeneration in the presence of damage, such as
bone lysis process related to peri-implantitis, is vascularization. Clot formation and immune
inflammatory responses are early biological events of peri-implant bone healing. Cells involved
in such process in this microenvironment produce cytokines, and growth factors (i.e., PDGF, FGF;
IGF; VEGF; BMP; IL1; TNF a needed to recruit osteogenic and vascular progenitor cells able to deposit
extracellular matrix and its subsequent mineralization and to drive the process of neovascularization.
To date, several strategies have b en evaluat d to improve bone regeneration under these conditions;
however, little attention h s been given to enhancing the vasculariz tion arou d the implant [30–35].
The improvements of vascularization during bone regeneration related to use of enriched scaffolds are
mainly correlated to the application of bone-like substitutes enriched on cells, growth factors of 3D
structure. The use of VEGF on bone regenerations has been firmly studied in detail by Kempen [36],
Kaigler [37], and Leach JK [38], that enriching different bone substitutes with VEGF confirmed that
a high bone regeneration was present. In this view, no attention has ever been related to the enrichment
of this growth factor on titanium surfaces.
In this study, a de tal implant coated with VEGF has been designed and us d as a platform
to improve ost genesis and angiogenesis. In this context, VEGF represents the natural s imulant,
and DPSCs the cellular model. In detail, VEGF-enriched implants served as substrate to support cell
adhesion, survival and differentiation. The MTT assay result was slightly higher for cells cultured
on this type of implants compared to that of the unmodified implants on days 7–28; this was true
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also in the presence of inflammatory cytokines that usually are known to influence cell proliferation.
In general, the MTT results show that the DPSCs grown on the VEGF-enriched implant exhibited
higher proliferation rate than those seeded on the control one, both in normal and under inflammatory
conditions. Interestingly, the presence of VEGF on the implant’s surface seems to protect the stem
cells from senescence related to their in vitro aging process and to the presence of inflammatory
cytokines. In our study, we additionally compared the endothelial differentiation of the cells cultured
in presence of or without the inflammatory cytokine TNFα. Also in this case, the presence of VEGF
on the dental implants actively improves the endothelial commitment of DPSCs, as demonstrated
by the high percentage of CD31-positive cells. Lastly, the osteogenetic process has been evaluated
by means of gene expression analyses. We observed that the interaction between VEGF-implant
resulted in the upregulation of several osteogenic differentiation markers in DPSCs. Stem cells possess
indeed the ability to differentiate into osteogenic cells when they are cultured under endothelial
differentiation conditions.
4. Materials and Methods
4.1. Dental Implants
Dental implants were supplied by Ditron Dental (Ashkelon, Israel). In particular, MPI—Molecular
Precision Implants with dimensions of 8 mm × 4.2 mm enriched with VEGF were used for the in vitro
tests (Figure 9). The same implants without VEGF were used as control implants.
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4.2. Quantitative Analysis of VEGF Release
VEGF release from titanium dental implant was meas red in the culture medium at selected
time points (1 h, 6 h, 12 h, 24 h, 3 days, 7 days) using the Human VEGF ELISA kit (Sigma-Aldrich,
Saint Louis, MO, USA). We used 5 implants for each time point, results report the average of the
different bathes value.
4.3. DPSCs Isolation and Seeding onto Dental Implant
Human dental pulps were extracted from healthy molar teeth of subjects, who had given
written consent. Human DPSCs isolation was performed according to our previously published
protocol [39]. The isolated cells were then cultured with Dulbecco’s Modified Eagle Medium (DMEM)
(Lonza S.r.l., Milano, Italy) plus 10% Fetal Bovine Serum (FBS) (Bidachem S.p.A., Milano, Italy) and
1% Penicillin/Streptomycin (P/S) (EuroClone, Milan, Italy) to form complete DMEM (cDMEM).
At confluence, cells have been detached from the culture plates using 0.25% trypsin (EuroClone, Milan,
Italy), then seeded onto control and VEGF-enriched titanium implants at a density of 1 × 105 cells per
implant. For treat ent under inflam atory conditions, cells were cultured on both types of i plants in
presence of 10 ng/mL of TNFα (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were maintained
in culture up to 28 days, changing the medium twice a week.
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4.4. MTT Assay
To determine the proliferation rate of cells grown onto control and VEGF-enriched implants,
the MTT (methyl thiazolyl-tetrazolium)-based cytotoxicity assay was performed according to the
method of Denizot and Lang with minor modifications [40,41]. The test is based on mitochondrial
viability, i.e., only functional mitochondria can oxidize an MTT solution, giving a typical blue–violet
end-product. After harvesting the culture medium, the cells were incubated for 3 h at 37 ◦C in
1 mL of 0.5 mg/mL MTT solution prepared in Phosphate Buffer Saline (PBS, EuroClone) solution.
After removal of the MTT solution by pipette, 0.5 mL of 10% dimethyl sulfoxide in isopropanol (iDMSO)
was added for 30 min at 37 ◦C. For each sample, absorbance values at 570 nm were recorded in duplicate
on 200 µL aliquots deposited in 96-well plates using a multilabel plate reader (Victor 3, Perkin Elmer,
Waltham, MA, USA). All samples were examined after 3, 7, 14, 21 and 28 days from seeding.
4.5. LDH Activity
LDH activity was measured using a specific LDH Activity Assay Kit (Sigma-Aldrich) at 3, 7, 14, 21
and 28 days of cell culture. All conditions were tested in duplicate. The culture medium was reserved
to determine extracellular LDH activity. The intracellular LDH activity was estimated after cells lysis
with the assay buffer contained in the kit. All samples were incubated with a supplied reaction mixture,
resulting in a product whose absorbance was measured at 450 nm using Victor 3 plate reader.
4.6. ROS Measurements
The OxiSelect™ ROS Assay Kit (Cell Biolabs, Selangor, Malaysia) was used for measuring
intracellular ROS activity. The assay employs the fluorogenic probe DCFH-DA, which is cell permeant.
After deacetylation by cellular esterases, the probe is trapped as the non-fluorescent DCFH. Inside the
cell, DCFH reacts with intracellular ROS to form the fluorescent product DCF. The fluorescence was
recorded on the Victor 3 plate reader at 530 nm.
4.7. SA-b GAL Staining
Beta-galactosidase staining was performed using the Senescence-associated β-galactosidase
staining kit (Cell Signaling Technology, Danvers, MA, USA). DSPCs were fixed with a fixative solution,
and stained with the β-Galactosidase staining solution at 37 ◦C O/N. The number of positive and
negative cells were then counted in five random fields under the microscope, and the percentage of
SA-b GAL positive cells was calculated as the number of positive cells divided by the total number of
cells counted.
4.8. Cell Shape Analysis
Cell shape was evaluated on samples stained for 40 min with 5 mg/mL phalloidin. Briefly,
cells were fixed in 4% paraformaldehyde in PBS for 10 min, then permeabilized with 0.1% triton
X-100 (Sigma-Aldrich, Saint Louis, MA, USA) in PBS for 30 min at room temperature. Phalloidin was
then used for fluorescent staining of actin filaments, whilst nuclear staining was performed with
2 µg/mL Hoechst H33342 (Sigma-Aldrich) solution for 5 min. Images were acquired with the inverted
optical microscope DMI4000 B (Leica Microsystems, Wetzlar, Germany). Then, ImageJ software
(http://rsb.info.nih.gov/ij) was used to calculate cell area and different shape descriptors of at least
30 distinct cells. In detail, the Circularity (C), Roundness (R), and Solidity (S) of cells were calculated
according to the following equations [42]:
Circularity = C = 4piA/P2 (1)
where A is the cell area and P is the perimeter;
Roundness = R = a/b (2)
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where a and b are the width and length of the minimum bounding, respectively;
Solidity = S = A/ConvexA (3)
where ConvexA is the area enclosed by the smallest shell that borders all the points of the cell.
4.9. Immunofluorescence
Cells were fixed in 4% paraformaldehyde in PBS for 10 min, then incubated in 2% Bovine Serum
Albumin (BSA, Sigma-Aldrich) in PBS for 30 min at room temperature. Cells were incubated with
the rabbit polyclonal anti-human CD31 antibody (Abcam, Cambridge, UK) in 2% BSA solution in
a humidified chamber at 4 ◦C O/N. Immunofluorescence staining was performed using the secondary
antibody DyLight 549-labeled anti-rabbit IgG (H + L) (KPL, Gaithersburg, MD, USA) diluted 1/1000 in
2% BSA for 1 h at room temperature. Nuclear staining was performed with 2 µg/mL Hoechst H33342
solution for 5 min.
The percent of differentiated cells was calculated by counting the positive cells for CD31 compared
to the total number of cells present on the surface.
4.10. Real-Time RT-PCR
Total RNA was extracted from the DPSCs seeded onto VEGF-enriched or control dental implants
with the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany), including DNase digestion with the
RNase-Free DNase Set (Qiagen). For the first-strand cDNA synthesis, 500 ng of total RNA of each
sample was reverse-transcribed with the SensiFAST™ cDNA Synthesis Kit (Bioline, London, UK),
following the manufacturer’s protocol. Human primers were selected for each target gene using the
Primer 3 software. Real-time PCRs were run using the chosen primers at a concentration of 400 nM
and SensiFAST™ SYBR No-ROX Kit (Bioline) on a Rotor-Gene 3000 (Corbett Research, Sydney, NSW,
Australia). The thermal cycling conditions were as follows: 2 min denaturation at 95 ◦C; 40 cycles of
5 s denaturation at 95 ◦C; annealing for 10 s at 60 ◦C; and 20 s elongation at 72 ◦C. Differences in gene
expression were assessed with the 2∆∆Ct method [43] using DPSCs cultured in cDMEM on tissue
culture polystyrene as a control. Values were normalized to the expression of the Transferrin Receptor
(TFRC) internal reference, whose abundance did not change under our experimental conditions.
All experiments were conducted using three different preparations and repeated three times.
4.11. Statistical Analyses
The mean values for quantitative data were compared applying non-parametric Kruskal–Wallis
test for RT-PCR results. T tests were used to determine significant differences (p, 0.05). Repeatability was
calculated as the standard deviation of the difference between measurements. All testing was performed
in SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) (license of the University of Padua, Italy). Each test
has been performed on 5 different implants for each time point and repeated 3 times.
4.12. ALP Activity Measurements
The alkaline phosphatase (ALP) activity was measured after 3 weeks of cell culture to evaluate
the initial differentiation of MSC into preosteoblasts. Abcam’s Alkaline phosphates kit (colorimetric)
has been used to detect the intracellular and extracellular ALP activity. The kit uses p-nitrophenyl
phosphate (pNPP) as a phosphatase substrate which adsorbed at 405 nm when dephosphorylated
by ALP. According to the manufacturer protocol, the culture medium from each sample group was
collected and pooled together. At the same time, cells were washed with PBS and then homogenized
with ALP Assay Buffer (300 µL in total for each group) and centrifuged at 13,000 rpm for 3 min to
remove insoluble material. Different volumes of samples (medium and cells) were then added into
96-well plates, bringing the total volume in each well up to 80 µL with Assay Buffer; 80 µL of fresh
medium was also utilized as sample background control.
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Thereafter, 50 µL of 5 mM pNPP solution was added to each well containing test samples and
background control and incubated for 60 min at 25 ◦C, protecting the plate from the light. A standard
curve of 0, 4, 6, 12, 16 and 20 nmol/well was generated from 1 mM pNPP standard solution bringing
the final volume to 120 µL with Assay Buffer. All reactions were then stopped by adding 20 µL
of Stop solution into each standard and sample reaction except the sample background control
reaction. Optical density was read at 405 nm in a microplate reader (Victor). The results were
normalized subtracting the value derived from the zero standards from all standards, samples and
sample background control. The pNP standard curve was plotted to identify the pNP concentration in
each sample. ALP activity of the test samples was calculated as follow:
ALP activity (U/mL) = A/V/T (4)
where A is the amount of pNP generated by samples (in µmol). V is the amount of sample added in
the assay well (in mL). T is the reaction times (in minutes).
5. Conclusions
In conclusion, we have presented herein a novel titanium dental implant designed and
manufactured to promote vascularization. The results of our morphological, biochemical and biological
in vitro tests showed that the implant loaded with VEGF supported the growth and differentiation of
DPSCs also in the presence of an inflammatory environment. Although additional in vivo analyses
would lead to more positive conclusions, this VEGF-enriched implant could represent a good foothold
for improving the vascularization of dental implants also in cases of oral pathologies, such as
peri-implantitis. For this reason, in the future this novel developed implant could have great potential
for in vivo applications.
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